Paul Grayson is the president and CEO of San Diego-based Anaphore. Grayson was previously the president and CEO of Fate Therapeutics and a managing director of Sanderling Ventures. Over the last 10 years he has completed both private and public capital fundraising, delivering over $200 million for emerging companies. Transactions completed under Grayson’s watch produced over $150 million in recognizable revenue with an announceable value in excess of $1 billion dollars, and included agreements with BMS, Lilly, Warner Lambert, Merck, F. Hoffmann La Roche, Pharmacia Upjohn, Kraft Foods, Campbell's Soup, Nestle and the Coca Cola Company. Grayson was a founding member of the management team of Aurora Biosciences and the founding chairman, CEO and president of Senomyx, Inc. He was previously chairman of the board of directors for Naviscan PET Systems and CalciMedica, and active on the board of directors for Taligen Therapeutics and REN Pharmaceuticals. Grayson received his MBA from the University of California, Irvine and his B.A. in computer science and biochemistry from the University of California, Los Angeles.